Livestream
Special Interview
Video Streaming
Sunday, 28 February 2021 12:49

US authorises Johnson & Johnson's single-shot COVID-19 vaccine

Written by 
Rate this item
(1 Vote)

Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine - iHeart Radio

 

 

The United States on Saturday (Feb 27) authorised Johnson & Johnson's COVID-19 vaccine for emergency use, giving the nation a third shot to battle the outbreak that has killed more than 500,000 Americans.

The single-shot vaccine is highly effective in preventing severe COVID-19, including against newer variants, the Food and Drug Administration (FDA) said before approving it.

"The authorisation of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic," said the US regulator's acting director Janet Woodcock.

The FDA announced the emergency use authorisation for adults aged 18 and older following Friday's unanimous endorsement by the agency's panel of outside experts.

In large clinical trials, the vaccine's efficacy against severe disease was 85.9 per cent in the United States, 81.7 per cent in South Africa, and 87.6 per cent in Brazil.

Overall, among 39,321 participants across all regions, the efficacy against severe COVID-19 was 85.4 per cent, but it fell to 66.1 per cent when including moderate forms of the disease.

US President Joe Biden hailed the "exciting" announcement but warned the nation could not let its guard down.

"This is exciting news for all Americans, and an encouraging development in our efforts to bring an end to the crisis," Biden said in a statement after the J&J vaccine got the green light.

"But we cannot let our guard down now or assume that victory is inevitable."

J&J expects to produce at least a billion doses of its vaccine in 2021 and has signed supply deals for most of that.

The United States agreed to pay more than US$1 billion for 100 million doses and may purchase an additional 200 million doses//CNA

Read 506 times